Charles Bennett to Combined Modality Therapy
This is a "connection" page, showing publications Charles Bennett has written about Combined Modality Therapy.
Connection Strength
0.364
-
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016 May; 44:61-4.
Score: 0.107
-
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008 Sep 15; 113(6):1446-52.
Score: 0.064
-
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest. 2001; 19(2):107-13.
Score: 0.037
-
Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Stem Cells. 1995 Jul; 13(4):414-20.
Score: 0.025
-
Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells. 1994 Jul; 12(4):424-9.
Score: 0.024
-
The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013 Sep; 112(5):548-60.
Score: 0.022
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992 Feb 01; 116(3):177-82.
Score: 0.020
-
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
Score: 0.014
-
Hairy cell leukemia and mucormycosis. Treatment with alpha-2 interferon. Am J Med. 1986 Dec; 81(6):1065-7.
Score: 0.014
-
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14):2927-41.
Score: 0.012
-
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002 Jul 15; 95(2):361-76.
Score: 0.010
-
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999 Sep 01; 94(5):1517-36.
Score: 0.008
-
Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease. Anticancer Drugs. 1993 May; 4 Suppl 1:13-6.
Score: 0.005